Vertical: CNMBase Year: 2025
Market Size (2025)
$96.56M
Projected (2032)
$123.08M
CAGR (2022–2032)
3.5%
Key Players
9+
Market Overview
The Global Guanidinoacetic Acid Market was valued at USD 96.56 million in 2025 and is projected to reach USD 123.08 million by 2032, registering a CAGR of 3.53% over 2026–2032. The market has expanded steadily from USD 86.99 million in 2022, and between 2025 and 2032 it is expected to add an absolute value of USD 26.52 million. Guanidinoacetic acid (GAA) is a feed additive that acts as the direct metabolic precursor of creatine, the compound that stores and regenerates cellular energy in muscle tissue. Its commercial value rests on two effects that are well documented in poultry nutrition: improved feed conversion through better cellular energy supply, and partial sparing of arginine, an amino acid that birds cannot synthesise in sufficient quantities.
Demand for GAA is closely tied to the growth of intensive broiler production, the rising cost of feed protein and energy, and the steady widening of regulatory approvals to new species and to drinking-water application. The market remains relatively small in value terms but is strategically significant for feed additive suppliers because it offers a performance and cost-optimisation tool that integrators can apply across large volumes of compound feed.
Key Findings
By Livestock: Poultry is the largest segment, valued at USD 77.25 million in 2025 (80.0% share). Swine & Others is the fastest-growing segment, with a CAGR of 5.00% over 2026–2032.
By Physical Form: Powder is the largest segment, valued at USD 67.59 million in 2025 (70.0% share). Granules is the fastest-growing segment, with a CAGR of 4.85%.
By Region: Asia Pacific is the leading region, valued at USD 40.55 million in 2025 (42.0% share). Middle East & Africa is the fastest-growing region, with a CAGR of 4.85%, followed by Latin America at 4.28%.
By Country: China is the leading country market, valued at USD 18.25 million in 2025, while India is the fastest-growing country, with a CAGR of 5.99% over 2026–2032.
Segmentation Summary
Poultry dominates GAA consumption because the additive was first developed, tested and authorised for broiler chickens, and because arginine sparing is most relevant in birds. The segment grows from USD 77.25 million in 2025 to USD 95.88 million in 2032. The Swine & Others segment is smaller, at USD 19.31 million in 2025, but expands faster to USD 27.20 million by 2032 as approvals for pigs, including drinking-water use in the European Union, and research into other species broaden the addressable feed base.
By physical form, Powder accounts for USD 67.59 million in 2025 and remains the standard format for premix and feed mill dosing. Granules, at USD 28.97 million in 2025, grow faster to USD 40.37 million in 2032, reflecting the preference of large feed mills for dust-reduced, free-flowing grades that mix uniformly and are easier to handle.
Competitive Landscape Summary
The market is moderately consolidated at the branded, regulated end and fragmented at the commodity end. Two German companies hold the leading positions: Alzchem Group AG, which developed the GAA feed additive concept and markets the Creamino brand, and Evonik Industries AG, which markets GuanAMINO and received its own European Union authorisation in May 2026. A group of Chinese producers, including Beijing Gendone Biotechnology, Jiangsu Yuanyang Pharmaceutical, Hebei Daxiao Biotechnology and Shandong Fulikang Animal Nutrition, supplies a large part of global volume, competing mainly on price in Asia and in export markets. Regional distribution partners such as Behn Meyer in Southeast Asia and Protekta in Canada extend the reach of branded suppliers.
Challenges and Opportunities
The main challenges are the dependence of production on the energy-intensive calcium carbide and cyanamide chain, price competition from low-cost producers, and uneven regulatory status across countries and species, which limits use in pigs, ruminants and several emerging markets. Feed producers also require strong trial evidence before they assign nutritional matrix values to GAA, which slows adoption among smaller mills.
Opportunities arise from new species and application approvals (turkeys, breeders and drinking-water application in the European Union), rising protein and energy prices that increase the value of arginine and energy sparing, the shift toward lower crude protein diets, and fast-growing poultry and pork sectors in India, Southeast Asia, Brazil, Mexico and the Gulf states.
Future Outlook
The market is expected to grow at a CAGR of 3.53% between 2026 and 2032, reaching USD 123.08 million in 2032. Asia Pacific will remain the largest regional market, rising from USD 40.55 million in 2025 to USD 51.95 million in 2032, while Middle East & Africa and Latin America are set to gain share on the back of poultry sector expansion. Over the forecast period, competition is expected to centre on regulatory coverage, product form (granulated and water-soluble grades), technical service and proof of return on investment for integrators.
The Guanidinoacetic Acid Market market is projected to grow at a CAGR of 3.5% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Guanidinoacetic acid (GAA), also known as glycocyamine or N-amidinoglycine, is an organic compound with the molecular formula C3H7N3O2, a molar mass of 117.11 g/mol and CAS number 352-97-6. In animals, GAA is formed from arginine and glycine by the enzyme L-arginine:glycine amidinotransferase (AGAT) and is then methylated, mainly in the liver, by guanidinoacetate N-methyltransferase (GAMT) to form creatine. Creatine, as phosphocreatine, acts as an energy buffer that regenerates adenosine triphosphate (ATP) in muscle and other tissues.
Feed-grade GAA is produced by chemical synthesis, through the reaction of glycine with cyanamide in aqueous solution, followed by crystallisation, drying and, in some grades, granulation with a small amount of starch. It is supplied as a high-purity substance (typically 96% to 98% GAA or more) for inclusion in complete feed, premixes and, where permitted, drinking water. Typical inclusion levels in authorised uses are 600 to 1,200 mg per kg of complete feed.
Included in the scope: feed-grade guanidinoacetic acid and GAA preparations sold for animal nutrition, in powder and granule form, used in poultry, swine and other livestock, measured at the level of product sales by manufacturers and their distribution partners.
Excluded from the scope: creatine monohydrate and other creatine products, pharmaceutical, laboratory and human-nutrition grades of GAA, the value of complete feeds and premixes that contain GAA, and other amino acids or energy-related feed additives.
Scope of the Study
Segmentation by Livestock: Poultry; Swine & Others
Segmentation by Physical Form: Powder; Granules
Segmentation by Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)
Timeline: historic years 2022–2024; base year 2025; forecast period 2026–2032
Currency and unit: USD Million
Research Objectives
To estimate the size of the global guanidinoacetic acid market for 2022–2025 and forecast it for 2026–2032 in USD Million.
To analyse the market by livestock (Poultry; Swine & Others) and by physical form (Powder; Granules), identifying the largest and fastest-growing segments.
To assess regional and country-level demand across North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
To evaluate the drivers, restraints, opportunities and trends shaping GAA use in compound feed and drinking water.
To review the regulatory framework for GAA as a feed additive in major jurisdictions, including species- and application-specific approvals.
To examine the value chain, from cyanamide and glycine inputs to feed mills, premixers and livestock integrators.
To profile the competitive structure of the market, including the positioning of leading producers and their key developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured process that combined secondary research, primary research and quantitative modelling. The process began with a definition of the product scope and segmentation, followed by the collection of production, consumption, trade and pricing information for GAA and for the livestock sectors that use it. Market estimates were then built using top-down and bottom-up approaches, validated through primary interviews with industry participants, and triangulated to arrive at final values for each segment, region and country.
Scoping: definition of the product, application areas, physical forms and geographic coverage.
Data collection: secondary research on the feed additive, poultry and swine industries, followed by primary research with supply-side and demand-side participants.
Market estimation: construction of top-down and bottom-up models for the base year 2025 and historic years 2022–2024.
Forecasting: projection of the market to 2032 using demand drivers, regulatory developments and price trends.
Validation: triangulation of estimates and review of results with industry experts.
Secondary Research
Secondary research provided the foundation for understanding the GAA value chain, regulatory status and the size of the end-use livestock sectors. The following types of sources were consulted:
Industry associations: feed manufacturers' and premix associations, poultry and pork producer associations, and animal nutrition federations that publish compound feed and livestock statistics.
Government and regulatory bodies: feed additive authorisation registers and scientific opinions (for example, the European Food Safety Authority and the European Commission feed additive register), U.S. Food and Drug Administration feed additive regulations, the Canadian Food Inspection Agency feed ingredient table, agriculture ministries, and statistical agencies such as USDA and FAO.
Company filings: annual reports, investor presentations, product data sheets and press releases of GAA producers and animal nutrition companies.
Trade journals and scientific literature: animal nutrition and feed industry publications, peer-reviewed studies on GAA efficacy in poultry and pigs, and conference proceedings.
Paid databases: trade and customs databases for GAA and related chemicals, company information databases and commodity price databases for feed ingredients.
Primary Research
Primary research was conducted to validate secondary findings, fill information gaps and obtain qualitative insight into market dynamics. Interviews were held with participants across the value chain.
Supply side: GAA manufacturers, cyanamide and glycine suppliers, product managers of animal nutrition companies, and regional distributors of specialty feed additives.
Demand side: nutritionists at integrated poultry and pig producers, feed mill and premix company managers, veterinary and technical service specialists, and procurement managers.
Objectives: to validate market size and segment splits, understand inclusion practices and adoption barriers, assess pricing and competitive dynamics, and test forecast assumptions for each region.
Market Size Estimation
Top-down approach: the total compound feed volume for poultry and swine in each country was used as the starting point. Adoption rates for GAA, average inclusion rates within the authorised range and average selling prices were applied to estimate the value of GAA consumed. Regional totals were then summed to derive the global market.
Bottom-up approach: the market was built from the supply side by estimating the GAA sales of leading producers and distributors, using production capacity information, company disclosures, trade data and interview inputs, and aggregating these to regional and global totals.
Data triangulation: the results from both approaches were compared and reconciled. Differences were investigated through additional primary interviews and secondary checks until the estimates converged. Segment splits by livestock and physical form were applied at the country level and aggregated to regional and global levels to ensure consistency.
Forecasting Methodology
The forecast was developed by projecting the key demand variables for each country and segment. Factors considered include:
Growth in broiler, turkey, layer and pig production and in compound feed output.
Regulatory approvals for new species and application routes, including drinking water.
Adoption rates among integrators and feed mills, and the use of GAA matrix values in feed formulation.
Feed ingredient prices, particularly protein meals, feed fats and synthetic amino acids.
Average selling price trends, influenced by raw material and energy costs and by competition.
Animal disease outbreaks, trade policies and macroeconomic conditions.
Forecasts were generated through a combination of trend analysis, driver-based modelling and expert judgement, and reviewed against the historical development of the market from 2022 to 2025.
Assumptions and Limitations
Market values are expressed in nominal USD Million; the effect of currency fluctuations is not modelled separately.
The regulatory framework in each country is assumed to remain broadly stable, with new approvals following the pattern of recent years.
No major disruption to global livestock production beyond the disease and trade pressures observed in recent years is assumed.
Company-level GAA revenue is not disclosed by most producers, so supply-side estimates rely on capacity, trade and interview information.
Some producers, particularly in China, publish limited information, which increases uncertainty in supply-side estimates for Asia Pacific.
Values are rounded to two decimal places in the tables; small differences in totals may arise from rounding.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global guanidinoacetic acid market has a two-tier structure. At the branded, regulated end, the market is moderately consolidated: two German companies, Alzchem Group AG and Evonik Industries AG, hold the principal regulatory authorisations in the European Union and supply branded products backed by efficacy data and technical service. At the commodity end, the market is fragmented, with several Chinese producers supplying powder and granulated GAA to domestic feed companies and to export markets, competing mainly on price.
Competition is based on regulatory coverage by species and application, product quality and form, technical service and the ability to demonstrate return on investment to integrators and feed mills. Because GAA is a defined chemical substance, product differentiation relies on purity, physical properties (dust, flowability, solubility), supporting research and supply reliability. Regional distribution partners play an important role in markets where producers do not have their own sales organisations. The European Union authorisation granted to Evonik in May 2026 ended the single-holder position in Europe and is expected to intensify competition in the region.
Key Player Positioning
Market Leaders
Alzchem Group AG (Germany): the originator of GAA as a feed additive and the holder of the original European Union authorisations, marketed under the Creamino brand. Alzchem produces GAA at Trostberg, Germany, using its integrated calcium carbide and cyanamide (NCN) chain, which gives it control over key raw materials. The company sells directly and through distribution partners, and has continued to extend approvals to new species and to drinking-water use. Alzchem reported group revenue of EUR 562.1 million for FY2025.
Evonik Industries AG (Germany): a global specialty chemicals company whose Animal Nutrition business markets GuanAMINO, a granulated, low-dust GAA product, alongside its amino acid range. Evonik uses its global feed industry sales and technical service network and received its own European Union authorisation for chickens and turkeys in 2026. It is also investing in fermentation-based production technology. Evonik reported group revenue of EUR 14.1 billion for FY2025.
Challengers
Beijing Gendone Biotechnology Co., Ltd. (China): a feed additive company focused on functional amino acids, with GAA as its flagship product, marketed under brands such as NutriBuilder and including a water-soluble formulation for pigs. Production is carried out by its subsidiary in Gu'an, Hebei. The company is active in standards development and technical publications in China. It reported revenue of RMB 152.2 million for FY2025.
Jiangsu Yuanyang Pharmaceutical Co., Ltd. (China): a manufacturer of guanidino compounds, including glycocyamine (GAA), creatine monohydrate and taurine, supplying feed and chemical customers in China and export markets. Revenue is not publicly disclosed.
Niche Players and Regional Partners
Hebei Daxiao Biotechnology Co., Ltd. (China): a smaller producer of GAA powder and glycine chelates for feed, serving domestic and export customers. Revenue is not publicly disclosed.
Shandong Fulikang Animal Nutrition Co., Ltd. (China): a feed additive and premix producer offering a fat-coated GAA product aimed at ruminants as well as pigs and poultry. Revenue is not publicly disclosed.
Hebei Boyu Biotechnology Co., Ltd. (China): a small new entrant whose project for 400 tonnes per year of GAA, together with metal proteinate products, received environmental approval in 2025. Revenue is not publicly disclosed.
Behn Meyer (Germany / Southeast Asia): a specialty chemicals distributor that has been the exclusive partner for Creamino in seven Southeast Asian countries since 2019. Revenue is not publicly disclosed.
Protekta (Canada): a feed additive distributor that has been the sales and distribution partner for Creamino in Canada since 2021. Revenue is not publicly disclosed.
Competitor Dashboard
The dashboard below rates the profiled companies on four qualitative criteria, based on publicly available information and industry interviews.
Threat of New Entrants – Medium
Production technology is established and capital requirements are moderate, which allows new producers, particularly in China, to add capacity.
Regulatory dossiers for the European Union, the United States and other regulated markets require substantial time and investment, protecting established suppliers in these regions.
Access to cyanamide supply and technical service capabilities are additional barriers for new entrants.
Bargaining Power of Suppliers – Medium
Cyanamide production is concentrated among a limited number of producers, giving them some pricing power.
Glycine is widely available from multiple producers, which limits supplier power for this input.
Energy costs pass through the carbide and cyanamide chain, affecting non-integrated GAA producers.
Bargaining Power of Buyers – High
Buyers include large integrators, feed groups and premix companies that purchase in volume and negotiate on price.
Buyers can compare multiple suppliers, especially in Asia where several producers compete.
Adoption depends on demonstrated return on investment, giving buyers leverage in negotiations.
Threat of Substitutes – Medium
Direct supplementation of arginine or creatine can partly substitute for GAA, though usually at higher cost or with lower stability.
Other feed efficiency additives, such as enzymes and specialty energy sources, compete for the same additive budget.
GAA's specific role as a creatine precursor and its authorised claims limit direct substitution in many applications.
Intensity of Competitive Rivalry – High
Two established branded suppliers compete with several Chinese producers on price, product form and service.
The entry of a second authorised supplier in the European Union in 2026 increases competition in a key regulated market.
Product differentiation is limited by the chemical identity of GAA, increasing the importance of technical service and regulatory coverage.
Threat of new entrants: Medium.
Bargaining power of suppliers: Medium.
Bargaining power of buyers: High.
Threat of substitutes: Medium.
Intensity of competitive rivalry: High.
Market estimates by geography (2032)
InsightAsia Pacific leads with $51.95M by 2032, while Middle East & Africa is projected to grow fastest at a 4.9% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $16.05M | $18.42M | $21.29M | 2.9% | 17% |
| Europe | $16.18M | $18.36M | $21.03M | 2.7% | 17% |
| Asia Pacific | $36.30M | $43.53M | $51.95M | 3.6% | 42% |
| Latin America | $13.45M | $16.81M | $20.73M | 4.4% | 17% |
| Middle East & Africa | $5.01M | $6.38M | $8.07M | 4.9% | 7% |
| Total | $86.99M | $103.50M | $123.08M | 3.5% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$123.08M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Poultry | $95.88M | 3.1% | 78% |
| Swine & Others | $27.20M | 5.1% | 22% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Guanidinoacetic Acid Market covering market dynamics, competitive landscape, and strategic outlook.
The Guanidinoacetic Acid Market market is projected to reach $123.08M by 2032, growing at 3.5% CAGR. The Poultry segment holds the largest share.
The Global Guanidinoacetic Acid Market is shaped by the growth and intensification of poultry and pig production, by the cost of feed protein and energy, and by the regulatory framework that defines where and how GAA can be used. This chapter assesses the macro and micro factors influencing the market, followed by a discussion of drivers, restraints, opportunities, and key trends and challenges. The impact scores presented in the growth factor analysis are analyst assessments based on secondary research and industry interviews, scored on a scale of 1 (low impact) to 10 (high impact) for three periods of the forecast.
Expansion of Global Poultry Production
Poultry is the world's fastest-growing meat category and the core end market for GAA. The U.S. Department of Agriculture's Foreign Agricultural Service, in its October 2026 Livestock and Poultry: World Markets and Trade report, estimates world chicken meat production at 112.4 million tonnes in 2026 and forecasts 114.9 million tonnes in 2027, with China, Brazil, the European Union and the United States accounting for much of the gain. Over the longer term, the OECD-FAO Agricultural Outlook 2026–2035 projects that poultry will deliver the largest absolute increase in meat consumption over the next decade. Broiler feed is already the largest category of compound feed globally; the Alltech Agri-Food Outlook 2026 placed broiler feed output at about 400 million tonnes in 2025. Because GAA is dosed at fixed rates per tonne of feed, every increase in broiler feed volume directly enlarges the addressable market. Fast-growing broiler strains also have high muscle energy demand, which supports the use of creatine precursors to maintain growth performance and breast meat yield.
Rising Feed Costs and the Value of Arginine Sparing
Feed accounts for the majority of the cost of producing broilers and pigs, so nutritionists continually look for ingredients that lower cost per kilogram of live weight. GAA spares arginine, because dietary creatine supply reduces the amount of arginine the bird must divert to endogenous creatine synthesis. The U.S. Food and Drug Administration regulation for GAA (21 CFR 573.496) explicitly recognises its use to spare arginine in broiler chicken and turkey feeds. Arginine is often a limiting amino acid in low-protein, plant-based poultry diets, and supplementing it directly is expensive. Protein and energy ingredient prices have been volatile: World Bank commodity data show soybean meal peaking at around USD 605 per tonne in early 2023 and fish meal prices rising sharply in 2026. When protein prices rise, the economic case for GAA strengthens, as nutritionists can assign it a matrix value and reduce the inclusion of costlier ingredients while maintaining performance.
Widening Regulatory Approvals
The regulatory coverage of GAA has expanded significantly since 2022, increasing the number of species and application routes that suppliers can address. In the European Union, Commission Implementing Regulation (EU) 2023/2628 authorised GAA for chickens reared for laying and breeding, in both feed and drinking water, and for drinking-water use in chickens for fattening. Regulation (EU) 2025/2505 extended authorisation to turkeys and to drinking-water use in weaned piglets and pigs for fattening, and Regulation (EU) 2026/1019 granted a second holder, Evonik, its own authorisation for chickens and turkeys. In the United States, approval was extended in 2021 to all poultry as a creatine precursor. Each new approval opens additional feed volume and allows suppliers to serve integrated producers across their entire flock, from breeders to broilers, which supports higher and more consistent adoption.
Shift Toward Efficient, Antibiotic-Free Production
Livestock producers are under pressure to raise productivity while reducing the use of antibiotics and the environmental footprint of production. Antibiotic growth promoters were banned in the European Union from 2006, growth-promotion claims for medically important antimicrobials were removed in the United States from January 2017, and China withdrew growth-promoting drug additives from commercial feed from July 2020 under Ministry of Agriculture and Rural Affairs Announcement No. 194. These measures have encouraged nutritionists to adopt non-antibiotic additives that support performance and feed efficiency. GAA is not an antibiotic substitute in a direct sense, but its effect on energy metabolism and feed conversion fits the broader strategy of precision nutrition. Suppliers also position GAA as a means to lower the carbon footprint of broiler production through better feed efficiency, which resonates with integrators and retailers that have committed to emission reduction targets.
Drinking-Water and Species Extensions
Authorisation of GAA in drinking water for chickens, turkeys and pigs in the European Union creates an application route that allows producers to target specific production phases, such as early growth, heat stress periods or the post-weaning phase in piglets, without reformulating feed. Pending reviews in other jurisdictions, such as the Canadian Food Inspection Agency's 2026 consultation on extending GAA to all poultry and swine, point to further expansion. Suppliers that develop water-soluble formulations and secure approvals early can capture this incremental demand.
Growth in Emerging Livestock Markets
Poultry and pig production in India, Southeast Asia, Brazil, Mexico, Saudi Arabia and other emerging economies is expanding and modernising, with a rising share of production from integrated operations that use compound feed and specialty additives. These markets show the fastest growth rates in the study, and awareness of GAA among nutritionists in these regions is still building. Local technical service, distribution partnerships and registration of GAA in national feed additive lists represent clear opportunities for suppliers.
Low-Protein and Sustainable Diet Formulation
The poultry and pig industries are moving toward reduced crude protein diets to lower nitrogen excretion, ammonia emissions and feed costs. Such diets rely on synthetic amino acids and on additives that improve nutrient efficiency. GAA, through arginine sparing and creatine supply, fits within this formulation strategy. Suppliers can also link GAA to sustainability goals through life-cycle assessment of feed efficiency improvements, creating a value proposition that goes beyond cost reduction.
Uneven Regulatory Status Across Countries and Species
Although approvals have widened, GAA remains unauthorised or only partly authorised in many markets. In the United States and Canada, approved use is limited to poultry, and authorisation for swine and ruminants is not yet in place. In several emerging markets, GAA is not yet clearly listed in national feed additive catalogues. Each new species approval requires efficacy and safety dossiers, which take years to prepare and evaluate. This uneven status restricts adoption, particularly in the Swine & Others segment, and limits the ability of global integrators to apply a uniform feeding strategy across their operations.
Raw Material and Energy Cost Exposure
GAA is produced from glycine and cyanamide. Cyanamide is derived from calcium cyanamide, which in turn is made from calcium carbide produced in electric-arc furnaces at very high temperatures. The production chain is therefore energy-intensive and exposed to electricity prices, particularly in Europe. Increases in energy and raw material costs can compress producer margins or lead to higher selling prices, which reduces the cost advantage of GAA relative to alternative feed strategies and may slow adoption among price-sensitive feed mills.
Need for Proven Return on Investment
Feed mills and integrators assign matrix values to an additive only when they are confident of consistent responses. Responses to GAA vary with diet composition, arginine and methionine levels, bird genetics and management conditions, and some studies have found no energy-sparing effect at standard inclusion levels. Regulatory authorisations in the European Union also require attention to vitamin B12 and methyl donors in diets containing GAA. These factors require technical support and on-farm trials, which raise the cost of market development, particularly among smaller producers.
Entry of a Second Authorised Supplier in Europe
Until 2026, the European Union authorisations for GAA were held by a single company. The authorisation granted to Evonik in May 2026 under Regulation (EU) 2026/1019 introduces a second holder for chickens and turkeys. This is expected to increase competition in Europe, broaden customer choice and intensify technical marketing activity.
Product Form Differentiation
Suppliers are differentiating through product form. Granulated, dust-reduced grades with improved flowability are favoured by large feed mills, while water-soluble formulations are being developed for drinking-water application. This trend underpins the faster growth of the Granules segment relative to Powder.
Alternative Production Routes
Research into fermentation-based production of GAA is advancing. Evonik has been granted U.S. patents covering fermentative production of GAA and GAA-producing microorganisms. If commercialised, such routes could reduce dependence on the cyanamide chain and change the cost structure of the industry over the long term.
Disease and Trade Disruptions
African swine fever continues to affect pig production in Asia and Europe; the World Organisation for Animal Health reports thousands of outbreaks in domestic pigs since 2022. Highly pathogenic avian influenza and related trade restrictions continue to affect poultry exports. Such disruptions can reduce feed volumes in affected markets and create short-term volatility in GAA demand.
The GAA value chain links basic chemical inputs to livestock producers through four main stages.
Raw materials and inputs: the main inputs are glycine and cyanamide. Cyanamide is produced from calcium cyanamide, which is obtained by reacting calcium carbide with nitrogen; calcium carbide is made from lime and coke in electric-arc furnaces. Electricity, water and packaging materials are other significant inputs. Producers integrated into the carbide and cyanamide chain have greater control over cost and supply security.
Manufacturing: GAA is synthesised by reacting glycine with cyanamide in aqueous solution, followed by crystallisation, filtration, drying and, for some grades, granulation with a small share of starch. Quality control focuses on purity and on limiting impurities such as dicyandiamide, cyanamide and melamine to the levels set by regulators.
Distribution and channels: producers sell directly to large premix companies, feed mills and integrators, and through regional distributors and traders. Products are usually supplied in 25 kg bags or 1,000 kg big bags. Distribution partners provide local registration, technical service and logistics in markets where producers lack their own sales teams.
End users: compound feed mills, premix and concentrate manufacturers, and integrated poultry and pig producers, which add GAA to complete feed or, where permitted, deliver it through drinking-water systems on farms.
European Union
Feed additives in the European Union are regulated under Regulation (EC) No 1831/2003 on additives for use in animal nutrition, which requires a scientific assessment by the European Food Safety Authority (EFSA) and an authorisation for each species and use, normally valid for ten years. GAA was first authorised for chickens for fattening under Commission Regulation (EC) No 904/2009. Commission Implementing Regulation (EU) 2016/1768 authorised GAA in feed for chickens for fattening, weaned piglets and pigs for fattening at 600–1,200 mg/kg of complete feed; these entries are authorised until 25 October 2026. Regulation (EU) 2023/2628 reclassified GAA as a zootechnical additive and authorised its use for chickens reared for laying and breeding, and in drinking water for chickens for fattening. Regulation (EU) 2025/2505 authorised GAA for turkeys and for drinking-water use in weaned piglets and pigs for fattening, and Regulation (EU) 2026/1019 authorised GAA in the name of Evonik Operations GmbH for chickens and turkeys. Simultaneous use in feed and water is not permitted.
North America
In the United States, GAA is an approved food additive for animal feed under 21 CFR 573.496. The regulation, originally issued in 2016 and amended in 2021, permits GAA in poultry feeds as a precursor of creatine and to spare arginine in broiler chicken and turkey feeds, at levels not exceeding 0.12% of complete feed, and sets purity specifications. In Canada, GAA is listed in the Canadian Feed Ingredients Table for broiler chickens and turkeys at up to 0.12% of complete feed under the Feeds Regulations, 2024; the Canadian Food Inspection Agency consulted in 2026 on extending its use to all poultry and swine.
Asia Pacific
In China, feed additives must be listed in the Feed Additive Catalogue maintained by the Ministry of Agriculture and Rural Affairs, and growth-promoting antibiotic additives were removed from commercial feed from July 2020 under Announcement No. 194. In Japan, the Ministry of Agriculture, Forestry and Fisheries designated GAA as a feed additive for broiler feed in 2019. In India, feed additive imports are governed by lists issued by the Department of Animal Husbandry and Dairying, and poultry feed quality is specified under the Bureau of Indian Standards standard IS 1374.
Latin America and Middle East & Africa
In Brazil, animal feed products and additives are regulated by the Ministry of Agriculture and Livestock (MAPA) under Decree No. 12,031 of 2024, which requires additives to be authorised and products to be listed or registered. In South Africa, farm feeds are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act (Act 36 of 1947). In the Gulf states, feed products are registered with national authorities such as Saudi Arabia's Ministry of Environment, Water and Agriculture. No Codex Alimentarius standard exists specifically for GAA; feed safety is addressed by the Codex Code of Practice on Good Animal Feeding.
Apr 2023: Evonik Industries AG; Restructuring; Restructured its Animal Nutrition business into separate operating models for amino acids and specialty nutrition products.
Nov 2023: Alzchem Group AG; Regulatory approval; Commission Implementing Regulation (EU) 2023/2628 authorised GAA for chickens reared for laying and breeding (feed and water) and for chickens for fattening (water), and reclassified GAA as a zootechnical additive.
Mar 2024: Alzchem Group AG; Regulatory assessment; The UK Food Standards Agency and Food Standards Scotland published their safety assessment of Creamino (GAA), concluding it is safe and efficacious for growing pigs and poultry.
Mar 2024: Beijing Gendone Biotechnology; Standard; A Zhongguancun group standard on guanidinoacetic acid, submitted by the company, came into effect.
Apr 2024: Beijing Gendone Biotechnology; Launch / partnership; Held a brand strategy and new technology launch in Beijing and released a GAA white paper with the National Feed Engineering Technology Research Center.
Jun 2024: Evonik Industries AG; Technology (patent); Granted U.S. Patent 11,999,982 covering the fermentative production of guanidinoacetic acid.
Mar 2025: Hebei Boyu Biotechnology; Capacity expansion; Received environmental approval for a project to produce 400 tonnes per year of GAA together with metal proteinate products in Xinle, Hebei.
Apr 2025: Alzchem Group AG; Regulatory; EFSA published scientific opinions on Creamino for turkeys and on its efficacy in drinking water for weaned piglets and pigs for fattening.
May 2025: Evonik Industries AG; Technology (patent); Granted U.S. Patent 12,312,622 for a microorganism producing guanidinoacetic acid.
Sep 2025: Beijing Gendone Biotechnology; Recognition; Its subsidiary Gu'an Gendone Biological Engineering was recognised as a Hebei Manufacturing Single-Champion Enterprise.
Dec 2025: Alzchem Group AG; Regulatory approval; Commission Implementing Regulation (EU) 2025/2505 authorised GAA for turkeys (feed and water) and for weaned piglets and pigs for fattening (drinking water).
Dec 2025: Alzchem Group AG; Investment; Approved a growth investment of about EUR 120 million in an automated plant for creatine and its precursors, with staged commissioning from the second half of 2027.
Dec 2025: Evonik Industries AG; Regulatory; EFSA published a scientific opinion on GuanAMINO for chickens and turkeys.
May 2026: Evonik Industries AG; Regulatory approval; Commission Implementing Regulation (EU) 2026/1019 authorised GAA in Evonik's name for chickens for fattening, chickens reared for laying and breeding, and turkeys, in feed and water.
Jul 2026: Evonik Industries AG; Market promotion; Promoted GuanAMINO and its arginine-sparing effect at SIAVS 2026 in São Paulo, Brazil.
Political
Government support for domestic poultry and pork self-sufficiency in Asia, the Middle East and Africa increases demand for productivity-enhancing feed additives.
Trade policies and import restrictions on poultry and pork affect feed volumes in exporting countries such as Brazil and the United States.
Economic
Volatile protein and energy ingredient prices strengthen the economic case for arginine- and energy-sparing additives.
Electricity and raw material costs in the cyanamide chain influence GAA production costs and selling prices.
Rising incomes in emerging economies support growth in animal protein consumption.
Social
Growing consumer demand for affordable protein, particularly chicken, supports broiler production growth.
Consumer and retailer preference for antibiotic-free meat encourages the use of non-antibiotic performance additives.
Technological
Development of granulated, dust-reduced and water-soluble GAA grades improves handling and application options.
Research into fermentation-based production routes may change production economics.
Precision nutrition and feed formulation software allow more accurate use of GAA matrix values.
Environmental
Improved feed efficiency can reduce the carbon footprint of poultry production, supporting sustainability targets.
Low-protein diets aimed at reducing nitrogen emissions create opportunities for GAA.
The energy-intensive production of calcium carbide and cyanamide is exposed to carbon pricing and emission regulation.
Legal
Species- and application-specific authorisations govern where GAA can be marketed.
Purity and impurity limits for dicyandiamide, cyanamide and melamine set quality requirements for producers.
Renewal procedures for existing authorisations require continued investment in regulatory dossiers.
Profiles of 103 companies operating in the Guanidinoacetic Acid Market market, including revenue, employee count, and market positioning where available.
Showing 103 of 103 companies
Evonik is Germany's second-largest listed chemicals group after BASF and one of Europe's broadest pure-play specialty chemicals companies, generating €14.1bn of sales and €1.87bn adjusted EBITDA in FY2025. Since April 2025 it has been organised into two operating segments — Custom Solutions (formulated, application-driven specialties for coatings, personal care, pharma, and industrial additives) and Advanced Technologies (scale- and technology-driven platforms in silica, hydrogen peroxide, high-performance polymers, crosslinkers and animal-nutrition amino acids) — plus an Infrastructure segment (SYNEQT site services, Oxeno C4 chemicals) earmarked for divestment. Its competitive identity rests on deep process know-how, integrated German Verbund sites (Marl, Wesseling, Rheinfelden, Essen, Hanau), and leadership positions in global niches (fumed silica, DL-methionine, PA12, pharma excipients/lipids). The investment case is a transformation story — €400m-plus cost reduction, portfolio pruning, deleveraging — now overlaid by a live takeover approach from BASF and a near-majority foundation shareholder whose stance is pivotal. --- ### Company self-description Evonik describes itself as a global chemical company that goes "beyond chemistry" by combining innovative strength with leading technological expertise, providing customers with a competitive advantage through tailor-made products and solutions — positioning itself as a "superforce for industry" (company boilerplate, press releases 2026; Company Factbook 2026). Its stated strategic pillars (Capital Markets Day, 22 May 2025) are: a differentiated portfolio in two segments, sustainable innovation, a balanced regional footprint (ambition of roughly one-third of sales in each of Americas, EMEA and Asia-Pacific), and a performance culture. ### Independent characterisation Evonik is a mid-cap, diversified specialty and "semi-specialty" chemicals manufacturer. Roughly 80% of FY2025 sales (€11.5bn of €14.1bn) came from the two core segments; the remaining ~18–19% came from Infrastructure & Other, which bundles low-margin site services and the cyclical C4 (Oxeno) petrochemical chain. The business is overwhelmingly a product business (manufactured chemicals sold B2B under supply contracts, frame agreements and spot), with smaller service/contract components: (i) pharma CDMO and contract manufacturing (Health Care — lipids/LNPs, drug substances, oral drug delivery), (ii) site infrastructure and utility services sold by SYNEQT to ~two dozen third-party companies in the Marl and Wesseling chemical parks, and (iii) licensing/technology (e.g., HPPO hydrogen peroxide technology with partners; catalysts). Subscription revenue is negligible. Precise revenue-model split (product vs service vs licensing) is n/d. ### Value-chain position Evonik sits mid-stream: it buys petrochemical feedstocks (C4 raffinate, propylene, methanol, ammonia, natural gas/energy, silicon metal, sulphur) and converts them into intermediates and formulated specialties sold to formulators and OEMs. Upstream integration is partial (own C4 cracking downstream of refinery/cracker streams at Marl and Antwerp; own HCN and methionine chain in Antwerp, Mobile and Singapore). Downstream, it rarely sells to consumers; its products are ingredients typically <5% of the customer's cost but critical to performance ("small cost share, high value-in-use"), which supports pricing power in the specialty businesses. ### Customer types and end markets Customers include paint and coatings formulators, adhesives and sealants makers, tyre and rubber producers (silica/silanes), cosmetic and household-care brands, pharmaceutical and biotech companies (excipients, lipids, CDMO), animal-feed mills and integrators (methionine), plastics and automotive suppliers (PA12, PEEK), aerospace (ROHACELL foams), pulp & paper, electronics and semiconductors (high-purity silanes/chlorosilanes, H2O2), renewable energy and hydrogen (membranes, catalysts), and biodiesel producers (alkoxide catalysts). End-market exposure is broad: consumer/personal care, health care, food/feed, automotive and mobility, construction, coatings, industrial, energy/agriculture. A precise end-market % split for FY2025 is n/d in sources reviewed.
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
RPM International is a holding company for more than a dozen semi-autonomous specialty-chemicals franchises. These businesses make coatings, sealants, roofing, concrete admixtures, flooring, fireproofing and building-envelope systems, mostly for maintenance, repair and restoration rather than new construction. Its brand portfolio is unusually deep for a USD 7.9 billion company: Rust-Oleum, DAP, Zinsser, Varathane and The Pink Stuff on the consumer side; Tremco, Euclid, Dryvit, Nudura, Kalzip, Stonhard, Carboline and Fibergrate on the professional side. Each brand holds a leading position in a niche that larger diversified coatings groups do not dominate. Since 2018 RPM has run successive operational-improvement programs (MAP to Growth, MAP 2025, and now "MAP 3.0"). These have lifted gross margin from about 36% (FY2022) to about 41% (FY2026) and moved the group from a loose federation toward a centrally coordinated operating company. RPM is a disciplined, dividend-growing compounder with 52 consecutive annual dividend increases. Its growth vectors are engineered building systems, emerging markets (the "Platform" model) and bolt-on M&A. --- ### Company's own description (FY2026 Form 10-K, Item 1) RPM describes itself as follows: its subsidiaries manufacture, market and sell specialty chemical product lines, including high-quality specialty paints, infrastructure rehab and repair products, protective coatings, roofing systems, sealants and adhesives. These products focus on the maintenance and improvement needs of the construction, industrial, specialty and consumer markets. Footprint as of 31 May 2026: - Products marketed in about 167 countries and territories. - Manufacturing in about 120 locations across 22 countries. - About 31% of sales generated internationally: foreign operations 29.8% of net sales, plus direct U.S. exports of 0.9%. The press-release boilerplate calls RPM "a world leader in specialty coatings, sealants, building materials and related services." ### Business model RPM's model has four defining features. - **Decentralised entrepreneurial structure, becoming more integrated.** The founder's philosophy, still quoted in the 2026 proxy, is: "Hire the best people you can find. Create an atmosphere that will keep them. Then let them do their jobs." Operating companies historically kept their own brands, sales forces and ERP systems. The MAP programs are deliberately centralising procurement, manufacturing, accounting and IT. The stated goal is to consolidate more than 75 ERP systems to one platform per segment (Q4 FY2026 8-K). **Repair and maintenance bias:** Much of the portfolio serves existing assets: roof restoration, re-cover, concrete repair, corrosion control, rust prevention and DIY touch-up. That demand is less cyclical than new-build construction. The FY2026 10-K notes that re-roofing has historically accounted for over three-quarters of U.S. roofing demand. **Systems and turnkey selling:** In CPG and PCG, RPM increasingly sells integrated systems (the "Power of One" building envelope) and supply-and-apply turnkey services. Examples include Stonhard flooring installation and Weatherproofing Technologies roofing services. This captures more of each construction project's spend. **Bolt-on M&A plus organic growth:** RPM completed six acquisitions in each of FY2025 and FY2026 (FY2026 10-K Note F). ### Revenue model mix RPM does not disclose a product versus service versus licensing split. From filings, the mix is: ### Value-chain position RPM is a formulator and brand owner, positioned downstream of commodity chemical producers. It buys petroleum-derived resins, solvents, pigments, minerals, metals and packaging (FY2026 10-K, Raw Materials). It is selectively backward-integrated: RPM cites expanding in-house raw material production, and Arnette Polymers makes amine curing agents and epoxy intermediates. Channels downstream include: - Mass merchants and home centres, where the single largest Consumer customer was 20% of Consumer sales in FY2026. - Hardware and paint stores. - Distributors. - Contractors and specifiers. - Direct sales to industrial plant owners, public institutions and infrastructure agencies. ### Independent characterisation RPM is best understood as a portfolio of niche category leaders with a structural margin-improvement story layered on top. The professional segments (CPG and PCG) are about 66% of sales and supply the growth. In FY2026 they posted record results driven by high-performance buildings, data centres, infrastructure, fireproofing and concrete admixtures. In Q1 FY2027, emerging-market regions grew more than 20%. The Consumer segment is about 34% of sales. It is a cash-generative but volume-challenged DIY business. Organic Consumer sales fell 0.8% in Q4 FY2026 and 4.7% in Q2 FY2026. They recovered to +5.2% in Q1 FY2027 on shelf-space wins and pricing. The equity debate therefore centres on three questions: 1. Can MAP savings and pricing protect margins against renewed raw-material inflation linked to the Middle East conflict? 2. Is the Q1 FY2027 CPG slowdown temporary? 3. Will the 9 November 2026 investor day credibly frame the next margin plan?
3 interactive charts drawn from the Guanidinoacetic Acid Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Guanidinoacetic Acid Market By Physical Form
Global Guanidinoacetic Acid Market By Livestock
Global Guanidinoacetic Acid Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
